Study ANRS0251s-HPVSign

The HPVsign study is a cross-sectional, non-comparative, multicentre study involving all participants included in the HPV sub-study of the ANRS IPERGAY trial. The study proposes to evaluate the cumulative incidence of high grade lesions (HSIL) and/or anal cancers, using high resolution anoscopy (HRA) during the HPVsign study and/or diagnosed since the end of participation in the ANRS IPERGAY trial.

Objectives

Primary:

• Assess the cumulative incidence of high-grade lesions and/or anal cancers objectified by the gold standard diagnostic test for these lesions, high-resolution anoscopy (HRA), during the HPVsign study and/or diagnosed since the end of participation in the ANRS IPERGAY trial.

Secondary:

• Study the association between the presence of high-grade lesions and/or anal cancer and the available HPV molecular signatures generated by Capture-HPV (capture + high-throughput sequencing) on sequential anal swabs obtained during participation in the ANRS IPERGAY trial.
• Study the association between the presence of high-grade lesions and/or anal cancer and the available HPV molecular signatures generated by Capture-HPV (capture + high-throughput sequencing) on sequential anal swabs obtained 10 years after inclusion in the ANRS IPERGAY trial (contemporaneous with AHR).
• Study the evolution of HPV molecular signatures between initial samples (obtained during participation in the ANRS IPERGAY trial) and samples taken 10 years later (persistence, evolution, integration).
• Compare the results of AHR with the results of anal cytology concomitant with AHR.
• Compare the results of anal cytology concomitant with AHR with those obtained during participation in the ANRS IPERGAY trial.
• Study the factors associated with the presence of high-grade lesions and/or anal cancer.
• Compare the presence of different types of HPV virus in the oropharynx concomitant with HRT and during participation in the ANRS IPERGAY trial.